Valuation: Geron Corporation

Market Cap 797M 699M 657M 601M 1.12B 76.31B 1.13B 7.89B 3.06B 38.91B 2.99B 2.93B 126B P/E 2026 *
-29.5x
P/E 2027 * 18.2x
Enterprise Value 797M 699M 657M 601M 1.12B 76.31B 1.13B 7.89B 3.06B 38.91B 2.99B 2.93B 126B EV / Sales 2026 *
3.37x
EV / Sales 2027 * 2.33x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-5.34%
1 week-3.88%
Current month-16.78%
1 month-18.42%
3 months-8.15%
6 months-19.48%
Current year-6.06%
1 week 1.22
Extreme 1.22
1.33
1 month 1.22
Extreme 1.22
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Director

6,103 0.0010%
5/20/26 Free

Director

220,000 0.0343%
5/20/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-5.34%-3.88%-7.46%-42.33% 842M
+0.06%+7.20%+54.04%+111.13% 74.27B
-2.29%-1.51%+33.30%+75.07% 61.21B
+0.28%+7.27%+31.74%+23.80% 27.55B
-2.05%-3.46%-18.60%+352.20% 26.38B
-2.39%+2.74%+0.19%-5.91% 25.34B
+0.57%+6.60%+26.25%-9.37% 20.84B
-1.47%+4.46%-8.09%+513.33% 14.94B
+1.29%-2.49%+163.31%+333.06% 15.17B
-2.44%-0.09%+42.50%+164.11% 14.41B
Average -1.38%+2.88%+31.72%+151.51% 28.1B
Weighted average by Cap. -0.97%+3.07%+35.42%+133.48%

Financials

2026 *2027 *
Net sales 236M 207M 195M 178M 333M 22.63B 336M 2.34B 908M 11.54B 887M 868M 37.41B 342M 300M 282M 258M 482M 32.76B 486M 3.39B 1.31B 16.7B 1.28B 1.26B 54.15B
Net income -27.18M -23.86M -22.43M -20.5M -38.31M -2.6B -38.6M -269M -104M -1.33B -102M -99.84M -4.3B 50.14M 44.01M 41.37M 37.82M 70.68M 4.8B 71.2M 497M 193M 2.45B 188M 184M 7.94B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-09-23 US$1.240 -5.34% 10,925,230
26-09-22 US$1.310 +0.77% 6,215,161
26-09-21 US$1.300 0.00% 5,897,021
26-09-18 US$1.300 -1.52% 17,244,691
26-09-17 US$1.320 +2.33% 9,819,461
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.240USD
Average target price
4.250USD
Spread / Average Target
+242.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock